Clinical Trial Update: VELCADE®-BEAM and Autologous Hematopoietic Stem Cell Transplantation for Non-Hodgkin's Lymphoma, or Mantle Cell Lymphoma [Phase 1, Phase 2]

View source ↗

Summary

Phase 1/2 trial evaluating VELCADE (bortezomib) with BEAM conditioning and autologous stem cell transplantation in non-Hodgkin's lymphoma and mantle cell lympho…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Mantle Cell Lymphoma
• Non-hodgkin Lymphoma

Drugs mentioned

• Velcade (bortezomib)

Snippet

Sponsor: University of Nebraska | Conditions: Non-hodgkin's Lymphoma, Mantle Cell Lymphoma | Phase 1, Phase 2 | Status: COMPLETED | Results posted: 2018-07-26